ACM
CYTK icon

ADAR1 Capital Management’s Cytokinetics CYTK Stock Holding History

ADAR1 Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-15,100
Closed -$710K – 224
2024
Q4 		$710K Hold
15,100
– – 0.14% 96
2024
Q3 		$797K Buy
15,100
+15,000
+15,000% +$836K 0.13% 92
2024
Q2 		$5.42K Sell
100
-2,400
-96% -$145K ﹤0.01% 242
2024
Q1 		$175K Sell
2,500
-70,700
-97% -$5.47M 0.04% 123
2023
Q4 		$6.11M Buy
+73,200
New +$2.65M 2.18% 10

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

ADAR1 Capital Management's CYTK Position: Q1 2026 in Review

ADAR1 Capital Management increased its Cytokinetics (CYTK) stake by 17% in Q1 2026, buying an estimated $5.87M and bringing the position to 632,556 shares worth $41.7M. The position accounts for 2.45% of the portfolio, ranked #7.

ADAR1 Capital Management first reported a position in CYTK in Q4 2023 and has held it in 10 quarters since. The position peaked at $48.1M in Q3 2024. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • ADAR1 Capital Management held 632,556 shares of Cytokinetics worth $41.7M as of Q1 2026.
  • ADAR1 Capital Management bought 92,390 Cytokinetics shares in Q1 2026, an estimated $5.87M.
  • Cytokinetics made up 2.45% of ADAR1 Capital Management's portfolio in Q1 2026, its #7 holding.
  • ADAR1 Capital Management first reported a position in Cytokinetics in Q4 2023 and has held it in 10 quarters since.
  • ADAR1 Capital Management's Cytokinetics position peaked at $48.1M in Q3 2024.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.